Hereditary transthyretin amyloidosis with polyneuropthy

Clinical trials for Hereditary transthyretin amyloidosis with polyneuropthy explained in plain language.

Never miss a new study

Get alerted when new Hereditary transthyretin amyloidosis with polyneuropthy trials appear

Sign up with your email to follow new studies for Hereditary transthyretin amyloidosis with polyneuropthy, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New study tracks Real-World safety of TEGSEDI for rare nerve disease

Knowledge-focused Ongoing

This study follows 240 patients with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) to monitor the long-term safety of the drug TEGSEDI. Researchers will compare patients who have taken TEGSEDI with those who have not, focusing on side effects like low platel…

Matched conditions: HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPTHY

Sponsor: Akcea Therapeutics • Aim: Knowledge-focused

Last updated Jul 31, 2026 00:00 UTC

Hereditary transthyretin amyloidosis with polyneuropthy

Get alerted when new Hereditary transthyretin amyloidosis with polyneuropthy trials appear

New study tracks Real-World safety of TEGSEDI for rare nerve disease